News

The partnership deals with integrating complementary capabilities and synergies of both the companies and plans for the long term supply of PAN resin and Zexlon film to Mitsui

Estonian Cancer Research Technology Development Center manager Riin Ehin was quoted by The Baltic Times citing Public Broadcasting as saying that production of the drug for rare types

Tafinlar is not indicated for the treatment of patients with wild-type BRAF melanoma, whereas Mekinist is not indicated for the treatment of patients who have received a prior

The agreement will help in the development of life science and protein assays by EMD Millipore for Luminex’s flexible platform. Under the terms of the agreement, EMD Millipore

Commenting on the agreement, ThromboGenics CEO Dr Patrik De Haes said, "This is an important step forward as we continue to build our ophthalmology franchise following the recent

Invented by Zealand and licensed to Helsinn, elsiglutide is a potent and selective glucagon-like-peptide-2 (GLP-2) receptor agonist and is developed for use in cancer supportive care. Helsinn evaluated

The fourth generation macrolide antibiotic is currently in Phase 3 development for community-acquired bacterial pneumonia (CABP) in adults. Cempra chief executive officer Prabhavathi Fernandes said BARDA has recognized

The Series A financing will be used to develop PH46A, as a potential first-in-class oral small molecule drug for the treatment of inflammatory bowel disease (IBD), as well

Expected to be issued in the next few months, the fifth US patent will provide additional protection to Zecuity, the sumatriptan iontophoretic transdermal system. Other US patents covering